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Abstract A cell surface-associated cathepsin G has been re- 
ported to be a possible complementary factor for H1V-1 infection 
of U-937 cells. The effect of recombinant gpl20 (IIIB) and a 
series of V3 loop peptides derived from the sequence of different 
strains of HIV on the activity of U-937 cathepsin G was assayed. 
The sequence on the N-terminal side of the highly conserved 
GPGRAF V3 loop segment was required for interaction with 
cathepsin G. The inhibition was stable for several hours and there 
was no cleavage of the peptides derived from the HIV-I(IIIB) 
strain. Recombinant gpl20 (IIIB) also remained uncleared after 
incubation with cathepsin G for 3 h, but some cleavage occurred, 
generating 2 fragments (50 kDa and 70 kDa), after 16 h. Linear 
peptides derived from HIV-1 Mal, ELI, MN, CDC4 and SF162 
strains, and consensus V3 peptides all had inhibitory properties 
towards cathepsin G, although they were significantly cleaved 
after one hour. The cleavage site was at the carboxy-terminus of 
Tyr 323 which is conserved in all these H1V-I strains but not in 
HIV-I(IIIB). There was no cleavage at the Arg residue of the 
GPGRAF sequence, whatever the V3 peptide sequence, the 
amount of proteinase, or the incubation time. We conclude that 
the inhibition of membrane-associated cathepsin G of U-937 cells 
by the gpl20 V3 loop of HIV-1 does not occur via a Kunitz-type 
mechanism, and that the proteinase-V3 loop interaction does not 
result in a significant cleavage of the V3 loop, though it has been 
suggested that this event is required for the entry phase of the 
virus. 
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1. Introduction 
It has been suggested that a variety of membrane compo- 
nents at the surface of HIV-1 permissive cells, including nega- 
tively charged components [1-7], proteinases [8 14], lectins [15] 
and integrins [16,17], can act as alternative or complementary 
factors to CD4, to allow the binding and entry of HIV-1. 
The main epitope involved in neutralizing HIV-1 is located 
within the V3 loop of the gp 120 molecule and discrete muta- 
tions at the crown of this loop may dramatically alter virus 
tropism and syncytium formation [18-22]. Hence, this fragment 
probably takes part in the process of virus-cell interaction at 
a later stage than CD4 binding [23]. 
*Corresponding author. Fax: (33) 47366046. 
Abbreviations: CHO, Chinese Hamster Ovary; DTNB, 5,5'-dithiobis- 
(2-nitrobenzoic a id); DTT, Dithiothreitol; h.p.l.c., high pressure liquid 
chromatography; NaCI/Pi, Phosphate buffered saline; Z-Lys-SBzl, 
N-c~-Cbz-L-lysine-thiobenzylester, HCI. 
A characteristic feature of the V3 loop, which could explain 
its importance in virus infection, is the presence at its tip of a 
conserved GPGRAF sequence which has a structure similar to 
the proteinase inhibitors of the Kunitz-2 family [24]. This pecu- 
liar feature xplains why a membrane associated proteinase was 
suggested to participate in HI¥-I  binding at the surface of 
sensitive cells [9]. Since then, several proteinases that may inter- 
act with peptides mimicking V3 loop sequences, have been 
identified, but there is as yet no proof that the interaction with 
a proteinase is a prerequisite for virus binding and fusion [8- 
14]. The proteolytic cleavage of the V3 loop by a membrane or 
endosomal proteinase also remains to be demonstrated. The 
identification of a preferential c eavage site at the arginyl resi- 
due of the GPGRAF sequence supports the proposal that V3 
loop may behave as a Kunitz-type inhibitor. This cleavage has, 
however, been observed only using recombinant gp120 ex- 
pressed in CHO cells, or in vitro upon incubation with large 
amounts of thrombin or lung tryptase [25,26]. No cleavage 
products have been identified uring virus-cell fusion or during 
syncytium formation [8,23]. The involvement of a proteinase to 
cleave the V3 loop and allow virus entry and infection, would 
indicate that the enzyme(s) responsible has a broad specificity 
and can act upon all HIV-1, and possibly HIV-2, strains. Tryp- 
tase TL2 from Molt4 lymphocytes, and membrane cathepsin 
G from U-937 cells both have a combined trypsin-like and 
chymotrypsin-like specificity, and both are inhibited by recom- 
binant gp120 via a V3 loop-dependent mechanism [9,14]. Sup- 
porting these observations, peptides reproducing the sequence 
at the tip of the V3 loop and including the conserved GPGRAF 
sequence inhibited tryptase TL2 and cathepsin G [9,11]. There 
was no indication however, that the GPGRAF sequence is 
involved in the interaction, or that a proteolytic cleavage within 
the V3 loop sequence occurs as a result of the interaction. We 
have therefore investigated this interaction using U-937 mem- 
brane cathepsin G and V3 loop-derived peptides of various 
lengths and sequences, to evaluate the capacity of membrane 
cathepsin G to interact with, and cleave the V3 loop of several 
strains of HIV-I. 
2. Material and methods 
2.1. Materials 
Enzymes. Membrane-associated cathepsin G was purified from U- 
937 monocyte-like cells as previously described [11,14]. Commercial 
neutrophil cathepsin G (E.C. 3.4.21.20) was obtained from ICN Bio- 
chemicals. 
Recombinant glycoproteins. Human immunodeficiency virus type 1 
gp120 (IIIB isolate) expressed in the baculovirus ystem, was obtained 
from American Biotechnologies Inc. (Cambridge, MA) via the U.K. 
Medical Research Council (MRC) AIDS Directed Program-Reagent 
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Project. Recombinant HIV-1 gp 120 (SF2 isolate) was expressed in 
Chinese hamster ovary (CHO) cells and obtained from the MRC. 
Synthetic peptides. Peptides R13K, V3 ELI, V3 MAL, V3 MN, 
SF162, V3 Cons and V3 Af. Cons were synthesized by the solid phase 
method of Atherton and Sheppard [27] using an automated Applied 
Biosystems 431 A peptide synthesizer. The cleaved and deprotected 
peptides were purified on an Aquapore RP300 CB column by high 
pressure liquid chromatography using a linear (0-60%) gradient of 
acetonitrile in 0.07% trifluoroacetic a id. Their purity was checked by 
amino-terminal sequencing on an Applied Biosystems 477 A peptide 
sequencer. 
Peptides SP88226, SP89046, SP89047, SP89364, SP89487, SP89488 
and V3 CDC4 were obtained from the Agence Nationale de Recherches 
sur le SIDA (ANRS), and V3b peptide was from Neosystem France 
(Strasbourg). V3 Cons and V3b peptides correspond to the consensus 
sequence reported by LaRosa et al. [28] and V3 Af. Cons peptide 
corresponds to the african consensus sequence deduced from the anal- 
ysis of 108 isolates [29]. 
Synthetic peptides containing carboxy-terminal cysteine were treated 
with 1 mM DTT and 2 mM iodoacetamide b fore incubation with 
U-937-proteinase. 
Monoclonal antibodies (MAb ) ( MN-A, l l O-D, l l O-H). These were 
obtained from F. Traincard (Pasteur Institute) and from the ANRS. 
They were raised against gpl20 (IIIB) and recognized epitopes located 
in the sequences 315-322 (MN-A), 317-325 (ll0-H) and 381-394 
(1 IO-D). 
2.2. Interaction between U-937 cathepsin G and HIV-1 gpl20, or 
synthetic peptides panning the V3 loop 
Inhibition by HIV-1 gpl20 (IIIB) was studied by incubating the 
U-937 or neutrophil cathepsin G (22.7 nM final concentration) for from 
one minute to three hours at 25°C in 0.10 M Tris-HC1 buffer pH 8.2, 
0.35 mM DTNB with increasing amounts of glycoprotein. The reaction 
was started by adding 20/11 Z-Lys-SBzl (0.38 mM final concentration) 
and the rate of hydrolysis was calculated by subtracting the background 
rate of absorbance increased at 412 nm from the enzyme-catalyzed rate; 
an extinction coefficient of 13,600 M -f. em -~ was used for the calcula- 
tion of the hydrolysis rate [30]. 
The gp 120 cleavage products were analysed by immunoblotting 
using monoclonal antibodies raised against two epitopes of the 
glycoprotein spanning the tip of the V3 loop and one directed against 
an epitope (381-394) in the 50 kDa C-terminal fragment. Recombinant 
glycoproteins (IIIB or SF2) (270 nM final concentration) were incu- 
bated without or with U-937 cathepsin G (300 nM final concentration) 
for from 15 rain to 16 h. Electrophoresis sample buffer (0.25 M Tris- 
HCI, pH 6.8, 2% SDS, 10% glycerol, 5% fl-mercaptoethanol, 0.1% 
Bromophenol blue) was then added to completely inhibit proteinase 
activity. The samples were boiled and separated by SDS-PAGE (7.5%) 
using the Phastsystem (Pharmacia). They were electroblotted onto ni- 
trocellulose (0.45 pm, Sartorius) by semi-dry electrotransfer fo  15 min 
at 25 mA. The nitrocellulose heet was incubated with NaCI/P~ (10 mM 
phosphate buffer, pH 7.4, 150 mM NaC1) containing 5% dried milk 
(W/V) at 37°C for 120 min and treated as previously described [31]. 
Monoclonal antibodies (10/tg/ml in NaCI/P~ containing 0.1% Tween-20 
and 5% dried milk) were added and incubated overnight at 4°C. The 
membrane was then washed three times with NaCl/P icontaining 0.05% 
Tween-20 and incubated with anti-mouse IgG-peroxydase conjugate 
(Sigma) (1/500 in NaCI/P~, 0.05% Tween-20, 1% dried milk) for 2 h at 
Table 1 
Inhibition of U-937 cathepsin G by gpl20 IIIB 
gp 120 IIIB (nM) Enzyme (nM) I/E Inhibition (%) 
22.7 22.7 1 27 _+ 2 
227.0 22.7 I0 35 +_ 2 
380.0 22.7 16 50 + 4 
U-937 cathepsin G (22.7 nM) was incubated with gpl20 IIIB for from 
one minute to three hours at 25°C in 0.1 M Tris-HC1, pH 8.2, contain- 
ing 0.35 mM DTNB, before starting the reaction with 20 ,ul of thioben- 
zylester substrate (0.38 mM final concentration). Absorbance was re- 
corded for 2 min at 412 nm. 
Mr  10 ~x 
120 II 71) .. 
50  
Ai A2 Bl B2 
Fig. 1. Immunoblotting of gpl20 (IIIB or SF2) incubated with U-937 
cathepsin G. GP 120 IIIB (Al, A2) and SF2 (Bt, B2) were incubated 
16 h with (A2, B2) or without (At, B0 U-937 cathepsin G. Mixtures were 
analyzed by SDS-PAGE and immunoblotting using monoclonal anti- 
bodies. Imrnunoreactive fragments were detected by chemilumi- 
nescence. 
room temperature and washed as before. Antigens were detected by 
chemiluminescence (ECL, Amersham) according to the manufacturer's 
instructions. 
The K~ value for the interaction between the R 13K inhibitory peptide 
and cathepsin G was determined using the Dixon plot [32] and inhib- 
itory properties of other peptides panning the V3 loop of gpl20 of 
different strains of HIV- 1, were compared to those of R 13K using these 
peptides at a single concentration. For this purpose, U-937 cathepsin 
G (6.2 nM final concentration) was incubated with increasing amounts 
of R13K (0-40/.tM) in 0.1 M Tris-HCl buffer, pH 8.2, 0.35 mM DTNB, 
for 15 rain at 25°C before starting the reaction with Z-Lys-SBzl used 
at two different concentrations (125 and 380/IM). V3 loop-derived 
peptides were used at a single concentration (32 ,uM final concentra- 
tion) and incubated with the same amount of cathepsin G (6.2 nM final) 
for 15 min, before adding the substrate (0.38 mM final concentration) 
and reading the absorbance at 410 nm. 
All peptides were also incubated with cathepsin G for longer times 
(up to 3 h) to check their stability. Mixtures were analysed by HPLC 
on an Aquapore ODS 032 column using a linear (0~80%) gradient of 
acetonitrile in 0.07% trifluoroacetic acid. When partial hydrolysis oc- 
curred, cleavage sites were determined by amino-terminal sequencing. 
Fragments i suing from the 3-h incubation of the V3 cons. peptide with 
cathepsin G, were reequilibrated in the activation buffer and assayed 
for their inhibitory properties, and the results compared to those ob- 
tained with the full-length peptide. 
3. Results 
3.1. Interaction between U-937 cathepsin G and gpl20 (II IB) 
The time-course of the interaction between purified cathep- 
sin G and recombinant gpl20 (IIIB) and any proteolytic leav- 
age of the molecule were studied using proteinase at 22.7 nM 
and varying the gpl20 (IIIB)/cathepsin G molar ratio from 
1 to 16 (Table 1). Maximal inhibition was obtained within one 
minute after mixing and it remained stable for at least 3 h at 
25°C. An identical result was obtained using commercial 
cathepsin G purified from human neutrophils. Western blotting 
revealed that there was no significant cleavage of the recombi- 
nant gpl20 (IIIB) within 3 h but cleavage into two fragments 
(70 kDa and 50 kDa) occurred after a 16 h incubation (Fig. 1). 
The Mr(app) of these fragments was consistent with cleavage 
within the V3 loop of the protein, as previously shown using 
thrombin as a proteolytic agent [25] or spontaneously cleaved 
gpl20 (SF2) produced in CHO cells [26]. However, the site of 
cleavage by cathepsin G was different from that of thrombin 
as shown using a monoclonal antibody directed against an 
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Fig. 2. Dixon plots for R13K peptide. U-937 cathepsin G (6.2 nM) was incubated for 15 min at 25°C with concentrations ofR13K from 0-40 pM 
(final) before starting the reaction with Z-Lys-SBzl (125 380 pM) as described in Table 1. Kinetic constant (K0 was determined according to Dixon 
(l/Vversus peptide concentration). 
epitope ncompassing the GPGRAF sequence that do not react 
anymore after cleavage of this sequence at its Arg site: Both the 
50 kDa and the 70 kDa fragments were recognized in gpl20 
(IIIB) after cathepsin G cleavage and immunoprinting using a 
mixture of Mab-110-D (directed against he 50 kDa fragment) 
and Mab-110-H and Mab-MN-A (both directed against he 
GPGRAFVT epitope). Under the same conditions the 70 kDa 
fragment was not recognized using recombinant gpl20 (SF2) 
spontaneously cleaved at the Arg site. Recognition of the 70 
kDa fragment generated by cathepsin G also indicates that the 
cleavage is on the C-terminal side of the GPGRAF sequence. 
3.2. Interaction between cathepsin G from U-937 cells and V3 
loop-derived peptides from gpl20 (IIIB) 
The interaction of cathepsin G with the V3 loop of gpl20 
(IIIB) was examined using synthetic peptides that included all 
or part of the GPGRAF sequence. The mechanism of inhibi- 
tion and the K~ were first determined using the peptide R13K. 
A competitive inhibition with a Ki value of 11 + 1 p was ob- 
served for the interaction between this peptide and U-937 
cathepsin G, using the Dixon plot, and working at two different 
substrate concentrations (Fig. 2). Preliminary attempts using 
related peptides howed that most had inhibiting properties 
similar to those of R l 3K, so that experimental conditions were 
standardized to allow comparison between all peptides using 
a single inhibitor concentration (Table 2). Under these condi- 
tions, all peptides behaved similarly, except hose lacking the 
N-terminal extension which includes a conserved ibasic dou- 
blet at position 309-310 (i.e. peptides SP89046 and SP89488). 
The results also show that the GPGRAF sequence was not 
required for inhibition, since peptide SP89487 which lacks the 
GRAF moiety, still inhibited cathepsin G, whereas peptide 
SP89046, which includes the whole sequence, did not (Table 2). 
As for gpl20 (IIIB), maximal inhibition by all inhibitory 
peptides occurred within one minute after mixing, and re- 
mained stable for at least 3 h. Reverse phase h.p.l.c, fractiona- 
tion of the reaction products from incubations for 3 h and for 
16 h, showed no significant cleavage of the peptides, confirming 
that the arginyl site of the GPGRAF sequence is resistant to 
cathepsin G hydrolysis (Fig. 3). 
3.3. Interaction between U-937 cathepsin Gand V3 loop-derived 
peptides from HIV-1 CDC4, ELI, MAL, MN, SF162 
strains and from consensus strains ( V3b, V3 cons, V3 
Af  Cons) 
We analysed the interaction between cathepsin G and V3 
loop peptides from different strains of HIV to ensure that they 
all inhibited proteinase activity. All the peptides were long 
enough (at least 29 residues) to include both the GPGRAF 
sequence or its equivalent (since this sequence is not conserved 
in all HIV-1 strains) and a dibasic doublet lying N-terminally 
to this sequence. The experimental conditions were standard- 
ized as before. 
As for gpl20 (IIIB)-derived peptides, inhibition was stable 
and almost immediate whatever the peptide sequence, but the 
percentage of inhibition was slightly lower than with V3 (IIIB)- 
Table 2 
Inhibition of U-937 cathepsin G activity by peptides of gpl20 IIIB 
spanning the crown of the ",13 loop 
Name Sequence Inhibition 
*(%) 
310 . . . . . . . .  320  
RI3K  RKSIRIQRGPGRK 56 + 6 
SP89047 TRPNNNTRKSIRIQRGPGRAFVT 58 + 2 
SP89364 CNTRKSIRIQRGPGRAFVTIGK 64 + 6 
SP88226 TRKSIRIQRGPGRAFV 58 + 2 
SP89487 TRKSIRIQRGP 40 +- 5 
SP89046 IRIQRGPGRAFVTIGK (n.s) 
SP89488 GRAFVTIGK (n.s) 
U-937 cathepsin G (6.2 nM final) was incubated with peptides (32 pM 
final) as described in Table 1. n.s: non significant; *mean of at least 
three experiments. 
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Fig. 3. HPLC analyses of the cleavage products of peptides, R 13K (a), V3 Cons (b) and V3b (c) deduced from the V3 loop sequence ofgpl20 IIIB 
(a) and from the consensus sequence ofLarosa et al. (b, c) by U-937 cathepsin G. Each peptide (32 pM final) was incubated with U-937 cathepsin 
G (6.2 nM) for 60 min (a, b) or 16 h (c) at 25°C in 0.1 M Tris-HC1, pH 8.2. Mixtures were fractionated on a C18 HPLC cartridge. 
derived peptides (Table 3). Unlike V3 (IIIB)-derived peptides, 
all peptides derived from other HIV-1 strains were significantly 
cleaved after one hour. These peptides differ from those derived 
from the HIV-1 (IIIB) strain by the presence of a Tyr residue 
at position 323, and the cleavage for all peptides was identified 
at this site by N-terminal sequencing. Prolonged incubation 
resulted in a minor cleavage on the C-terminal side end of 
Lys312, when it was present in the conserved ibasic doublet. 
This agrees with the combined trypsin-like and chymotrypsin- 
like specificity of cathepsin G [14]. This cleavage induced no 
change in the percentage of inhibition, which remains table for 
at least 3 h, indicating that cleavage isnot essential for interac- 
tion. Accordingly, h.p.l.c, purified N-terminal fragment ob- 
tained from the hydrolysis of V3 Cons. peptide, still inhibited 
U-937 cathepsin G. The consensus disulfide-linked V3 peptide, 
which is more closely related structurally tothe V3 loop within 
the gpl20, was cleaved only after 16 h incubation with cathep- 
sin G as was gpl20 IIIB. 
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Table 3 
Inhibition of U-937 cathepsin G by V3 loop peptides from different strains of HIV-1, or deduced from consensus sequences reported by Larosa et 
al. (V3 Cons.) and Myers et al. (V3 Af. Cons.) 
Name Sequence Inhibition *(%) 
310 .. . . . . .  320 ... . . . .  330 
I P I 
V3MN NNTYNKRKRIH IGPGRAFYTTKNI IGT IRRQAHC 30 ± 2 
V3Mal NNTRRGIHFGPGQALYTTGIVGDIRRAYC 31 ± 3 
V3 ELI YQNTRQRTPIGLGQSLYTTRSRSI IGQAHC 18 ± 2 
V3 CDC4 CHTRKRVTL-- -GPGRVWYTTGE 15 ± 1 
SF162 NTRKSIT IGPGRAFYATGDI  15 ± 2 
V3 Cons. NNTRKSIHIGPGRAFYTTGEI IGDIRQAHC 24 + 1 
V3 Af. Cons YNNTRQRTRIGPGQAFYTTGKI IGDIRQAHC 24 + 2 
U-937 cathepsin G (6.2 nM final) was incubated with peptides (32 ¢tM final) as described in Table 1. *Mean of at least hree experiments. 
4. Discussion 
There is little doubt as to the importance of the V3 loop in 
HIV-l-cell fusion, but the way it participates in this process is 
still a matter of debate. One possibility is that the V3 loop 
interacts with cell surface components via its conserved se- 
quences, but the precise role of putative candidates has not 
been elucidated. The V3 loop has an overall positive charge 
which may favour interaction with negatively charged com- 
pounds at the surface of host cells [5,33,34]. The V3 loop of 
gp120 could also interact with CD4 at a site different from the 
primary gp120 binding site [35], or with another cell surface 
protein able to accommodate a sequence as variable as that of 
the V3 loop [6,15-17]. It has also been recently suggested that 
the V3 domain could interact with other domains of gp120 
(V1/V2) and thus modulate the conformation of the glycopro- 
tein [36]. 
A cell surface proteinase has been proposed as the second 
receptor for HIV-1 because the crown of V3 loop has a con- 
served sequence that is similar to the inhibitory site of pro- 
teinase inhibitors of the Kunitz-2 family [24]. Consistent with 
this proposal, several inhibitors of serine proteinases and an 
antibody directed against he Molt4 surface proteinase tryptase 
TL-2, were shown to block syncytium formation [9]. Both 
Molt4 tryptase TL2 and U-937 cathepsin G are inhibited by 
gp120 and V3-1oop derived peptides. Neither cathepsin G was 
found at the surface of Molt4 cells by flow cytometry, nor 
tryptase TL2 at the surface of U-937 cells (unpublished data). 
Whether the presence of different proteinases at the surface of 
cells of the lymphocyte or macrophage lineages is related to the 
different ropisms of HIV strains remains however to be dem- 
onstrated. The question of how a proteinase with a very re- 
stricted specificity can interact with the hypervariable s quence 
of the V3 loop of all HIV-1 strains has recently been addressed 
[37]. The presence of a proteinase with broad specificity or of 
several proteinases has been suggested [23]. Tryptase TL-2 and 
cathepsin G both partly satisfy these conditions as they have 
a combined trypsin-like and chymotrypsin-like specificity 
[8,14]. 
Another possibility would be that the proteinase does not 
recognize gpl20 as a true substrate or inhibitor, but interacts 
with it through a less specific mechanism. Supporting this hy- 
pothesis, we found that the Kunitz-like sequence GPGRAF at 
the crown of V3 loop was not involved in the inhibition, since 
its C-terminal truncation does not alter the inhibitory proper- 
ties of V3 loop peptides. In contrast, the sequence located 
N-terminally with respect o this fragment, which contains a 
conserved ibasic doublet, is involved in the interaction. This 
suggests that a charge effect could participates in the interac- 
tion, as it was previously deduced from the observation that 
syncytium-inducing isolates have a significantly higher positive 
V3 loop charge than those of non-cyncytium-inducing isolates 
[39]. In order to check this hypothesis, peptides are now being 
synthesized substituting R309 and K310 with structurally related, 
uncharged residues. 
The reason why peptides reproducing the sequences of the 
different HIV-1 strains are less inhibitory than V3(IIIB)-de- 
rived peptides is not clear. Since these peptides, but not those 
derived from V3(IIIB), are also cleaved by cathepsin G, it could 
be that competition occurs between the C-terminal cleavage site 
and the N-terminal interaction site. Cleavage of Tyr-containing 
peptides caused no change in inhibitory properties, uggesting 
that inhibitory binding and hydrolysis are independent. Confir- 
mation is provided by the finding that h.p.l.c.-purified N-termi- 
nal fragments of cleaved peptides remain inhibitory towards 
U-937 cathepsin G. 
It is worth noticing that no cleavage at the R residue of the 
GPGR sequence was observed neither in recombinant gp120 
(IIIB) nor in V3-derived peptides uggesting that this cleavage 
previously observed with heterologous proteinases, was a fortu- 
itous event [9,25]. If the proteolytic function of cathepsin G is 
not directly involved in the interaction, the proteolytic cleavage 
of the V3 loop should not be essential for binding or the subse- 
quent events leading to virus entry and infection. The results 
presented here agree with this proposal, since recombinant 
gpl20 (IIIB) and peptides derived from its V3 loop sequence 
are resistant o proteolytic leavage. The question is now 
addressed as to know whether inhibitors of HIV infection, 
such as polyanionic ompounds [2 5,7], or betulinic acid deri- 
vatives [40], that are implicated at early, envelope-dependent 
stages, can inhibit cathepsin G at the surface of U-937 mem- 
branes. 
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